Can AstraZeneca's Motavizumab Leapfrog Synagis? Advisory Committee Will Weigh In
This article was originally published in The Pink Sheet Daily
Executive Summary
Panel meeting on the respiratory syncytial virus product - which demonstrated non-inferiority, but not superiority, to Synagis - is set for June 2.
You may also be interested in...
AstraZeneca's MedImmune Comes Closer To Motavizumab Approval, And A Tight Grip On RSV Market
AstraZeneca's biologics unit MedImmune is continuing to solidify its domination of the market for products to prevent serious respiratory syncytial virus disease in high-risk infants with a formal reply to FDA's "complete response" letter for its investigational product motavizumab
Glaxo and Pfizer Form HIV Venture, But A Spin-Off Could Be In The Wings
In a bid to patch over their respective weaknesses in the HIV marketplace, GlaxoSmithKline and Pfizer announced April 16 they are forming a jointly owned company combining their portfolios of existing and developing drugs
AstraZeneca Accelerates Biologics Strategy With Acquisition Of MedImmune
Following the merger, valued at roughly $15.6 billion, 27 percent of AstraZeneca’s portfolio will be in biologics.